Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment
2019 Recent Results Cancer Res
Jaroslawski, S. | Hanna, E. | Dabbous, M. | Chachoua, L. | Toumi, M. |
Decision Making, Medical Oncology/*economics, Resource Allocation, *Technology Assessment, Biomedical, Cost-effectiveness, Has, Health technology assessment, IQWiG/G-BA, Nice,
Rising budget constraints and demands for healthcare services create additional complexity within the decision process for resource allocation. Innovations and scientific progress have been shown to be key drivers of the increase in healthcare expenditures (1). In the context of rising medical care costs and limited resources, Health Technology Assessment (HTA) was developed as a tool to inform decision-making and to provide the rationalization behind these decisions driving resource allocation and spending for health technology products. Furthermore, HTA agencies make the decision-making process more transparent. The HTA approach involves evaluating multiple aspects of a new product’s value in order to maximize health gain provided within the setting of limited resources.